Workman P - Search Results

1

Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.

da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, Marais R. da Rocha Dias S, et al. Among authors: workman p. Cancer Res. 2005 Dec 1;65(23):10686-91. doi: 10.1158/0008-5472.CAN-05-2632. Cancer Res. 2005. PMID: 16322212

2

Multiparametric flow cytometry of the modulation of tumor cell membrane permeability by developmental antitumor ether lipid SRI 62-834 in EMT6 mouse mammary tumor and HL-60 human promyelocytic leukemia cells.

Dive C, Watson JV, Workman P. Dive C, et al. Among authors: workman p. Cancer Res. 1991 Feb 1;51(3):799-806. Cancer Res. 1991. PMID: 1988120

3

Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9.

Bailey SM, Wyatt MD, Friedlos F, Hartley JA, Knox RJ, Lewis AD, Workman P. Bailey SM, et al. Among authors: workman p. Br J Cancer. 1997;76(12):1596-603. doi: 10.1038/bjc.1997.603. Br J Cancer. 1997. PMID: 9413948 Free PMC article.

4

DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.

Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. Kelland LR, et al. Among authors: workman p. J Natl Cancer Inst. 1999 Nov 17;91(22):1940-9. doi: 10.1093/jnci/91.22.1940. J Natl Cancer Inst. 1999. PMID: 10564678

5

Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.

Clarke PA, Hostein I, Banerji U, Stefano FD, Maloney A, Walton M, Judson I, Workman P. Clarke PA, et al. Among authors: workman p. Oncogene. 2000 Aug 24;19(36):4125-33. doi: 10.1038/sj.onc.1203753. Oncogene. 2000. PMID: 10962573

6

Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.

Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Hostein I, et al. Among authors: workman p. Cancer Res. 2001 May 15;61(10):4003-9. Cancer Res. 2001. PMID: 11358818

7

HSP90 as a new therapeutic target for cancer therapy: the story unfolds.

Maloney A, Workman P. Maloney A, et al. Among authors: workman p. Expert Opin Biol Ther. 2002 Jan;2(1):3-24. doi: 10.1517/14712598.2.1.3. Expert Opin Biol Ther. 2002. PMID: 11772336 Review.

8

ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin.

Smith V, Hobbs S, Court W, Eccles S, Workman P, Kelland LR. Smith V, et al. Among authors: workman p. Anticancer Res. 2002 Jul-Aug;22(4):1993-9. Anticancer Res. 2002. PMID: 12174876

9

Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone.

Workman P. Workman P. Cancer Detect Prev. 2002;26(6):405-10. doi: 10.1016/s0361-090x(02)00126-5. Cancer Detect Prev. 2002. PMID: 12507224 Review.

10

Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.

Workman P. Workman P. Mol Cancer Ther. 2003 Feb;2(2):131-8. Mol Cancer Ther. 2003. PMID: 12589030 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

605 results

Search Page

Filters